ALPN - Alpine Immune Sciences Inc Stock Price, Fair Value and News

$7.40+0.10 (+1.37%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ALPN Price Action

Last 7 days

0.7%

Last 30 days

-0.7%

Last 90 days

-2.0%

Trailing 12 Months

4.9%

ALPN RSI Chart

ALPN Valuation

Market Cap

511.1M

Price/Earnings (Trailing)

-13.97

Price/Sales (Trailing)

9.1

EV/EBITDA

-15.95

Price/Free Cashflow

-6.35

ALPN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ALPN Fundamentals

ALPN Revenue

Revenue (TTM)

56.5M

Rev. Growth (Yr)

-25.09%

Rev. Growth (Qtr)

-77.21%

ALPN Earnings

Earnings (TTM)

-36.8M

Earnings Growth (Yr)

-35.07%

Earnings Growth (Qtr)

-400.64%

ALPN Profitability

EBT Margin

-56.76%

Return on Equity

-11.07%

Return on Assets

-9.86%

Free Cashflow Yield

-15.74%

ALPN Investor Care

Shares Dilution (1Y)

43.01%

Diluted EPS (TTM)

-0.64

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	56.5M	0	0	0
2023	25.8M	29.1M	30.8M	58.9M
2022	33.9M	32.0M	31.8M	30.1M
2021	11.4M	18.0M	24.6M	23.4M
2020	2.8M	3.0M	4.6M	9.3M
2019	0	1.1M	1.4M	1.7M
2018	1.5M	1.1M	910.2K	705.0K
2017	2.6M	2.3M	2.0M	1.7M
2016	0	0	1.7M	3.0M
2015	0	0	0	492.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Alpine Immune Sciences Inc

Alpine Immune Sciences, Inc., a clinical-stage company, focuses on immune therapeutics. The company has strategic collaborations immunotherapies via protein engineering technologies with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development. Its pipeline includes Povetacicept (ALPN-303), which is in a phase 1b, open-label study of povetacicept in autoimmune cytopenias, including immune thrombocytopenia, warm autoimmune hemolytic anemia, and cold agglutinin disease; and in phase 1b/2a, open-label study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, lupus nephritis, and primary membranous nephropathy. The company is also developing Acazicolcept (ALPN-101), which is in a phase 2 study of acazicolcept in patients with Systemic Lupus Erythematosus. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

CEO	Dr. Mitchell H. Gold M.D.
WEBSITE	alpineimmunesciences.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	126

Alpine Immune Sciences Inc Frequently Asked Questions

What is the ticker symbol for Alpine Immune Sciences Inc? What does ALPN stand for in stocks?

ALPN is the stock ticker symbol of Alpine Immune Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alpine Immune Sciences Inc (ALPN)?

As of Tue Nov 19 2024, market cap of Alpine Immune Sciences Inc is 511.05 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALPN stock?

You can check ALPN's fair value in chart for subscribers.

Is Alpine Immune Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether ALPN is over valued or under valued. Whether Alpine Immune Sciences Inc is cheap or expensive depends on the assumptions which impact Alpine Immune Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALPN.

What is Alpine Immune Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Nov 19 2024, ALPN's PE ratio (Price to Earnings) is -13.97 and Price to Sales (PS) ratio is 9.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALPN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Alpine Immune Sciences Inc's stock?

In the past 10 years, Alpine Immune Sciences Inc has provided -0.082 (multiply by 100 for percentage) rate of return.